QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 natera-to-expand-fetal-focus-test-to-cover-20-genes-marking-advancement-in-single-gene-noninvasive-prenatal-testing-new-expanded-panel-to-launch-in-q4-2025

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its...

 btig-maintains-buy-on-natera-raises-price-target-to-210

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $200 to $210.

 nateras-signatera-demonstrates-predictive-power-in-imvigor011-guiding-tecentriq-use-for-improved-bladder-cancer-outcomes

Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...

 canaccord-genuity-maintains-buy-on-natera-maintains-200-price-target

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and maintains $200 price target.

 natera-announces-publishes-signatera-validation-study-in-testicular-cancer-in-journal-of-clinical-oncology---precision-oncology

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers

 wells-fargo-initiates-coverage-on-natera-with-equal-weight-rating-announces-price-target-of-175

Wells Fargo analyst Brandon Couillard initiates coverage on Natera (NASDAQ:NTRA) with a Equal-Weight rating and announces Pr...

 neogenomics-gains-unexpected-win-as-court-rejects-natera-claims

NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boo...

 natera-patent-claims-against-neogenomics-radar-v11-invalidated-company-weighs-appeal-further-enforcement

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its int...

 natera-announces-activation-of-nrg-oncology-trial-archer-randomized-phase-iii-study-in-muscle-invasive-bladder-cancer

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrenceNatera, I...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION